Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If you go back and read thru lawsuit what nodder did with board and lies/votes to get him removed --it was pathetic. Then at court there was ZERO evidence presented for the "cause" nodder cited. Yet people defend nodder AND kelly. Pestell got on the outs because he would not enroll/use amawrecks for trial. Nodder had to have kickback dollars from khazem. Pestell took the fall
No one (even the conspiracy FDA/shorts/BP nonsense) can realize that if there was conspiracy, it was internal 100% . Check the "vanished' mods/posters here--at hangout--at redthread. P O O F
Dr pestell was only lwgitimate cancer doctor they ever had. Nader tried to take his shares and fire him. Dr. Pestell won in court. If dr pestell had been there full time,we would have cancer drug on market in my opinion
Im shocked shareholders dont want hee out
Why shocked?? Shareholders STILL defend nodder and blame FDA even AFTER Dr J made it 100% clear FDA wanted dosing done in S2C covid and after several Drs said it was necessary-- he refused
Shareholders STILL elected nodder years after he was found guilty TWICE (in court) of stealing from shareholders
Shareholders still blame Dr Pestell for phony acquisition even though nodder was CEO and got millions of free shares for it and SEC filed docs state EXACTLY what was being acquired
The list is long IF you know history I.E.--shareholders still blame amawrecks even AFTER the fraud was exposed and nodder used amawrecks AGAIN for MASH
The continued problem is that they dont focus on cancer. They are hiring hiv guy. They need to get rid of tanya who gives cydy nothing. She helps paulson ,but not shareholders. Im shocked shareholders dont want hee out. She has brought company to 13c. We need scientist to lead company not a paulson lawyer.
LOL!!! Wondered when the blame would go to "shorty"
Yeah, that must be it......the company was involved with fraud by the CEO. The company settled a lawsuit for far less money than promised. The new CEO has already stated the process is most likely 7 to 10 years from anything amounting in revenue. The new guy brought on board has stated any success takes years......
but it's "shorty's" fault the stock has gone from $1.45 to 13 cents over the last 3 years.
Oh yeah, and avg volume per day is around 1.5 million shares which equals less than $50k, so "shorty" must be using the slow burn method.
Of course, over the last 3 years there have been 3 different small spikes in volume. The stock rose, then quickly tanked again. It's almost as if there has been manipulation to pump then dump stock.
BTW, anyone can look at the charts for themselves. It's really obvious what goes on here.
Trade in a cash account. Not on margin. Or trade in your Retirement Account. However, it is a good idea to instruct your broker regardless.
If you decide to instruct your broker not to make your shares available for lending to short sellers, the following is a sample of the language you can use in your email or letter to the Branch Manager of your brokerage account:
[Broker Name]
[Broker Address]
Attn: Branch Manager
My Account [Account Number]
Dear Sir or Madam:
Please accept this written instruction to make sure that the following securities are held in my cash account only and accordingly are not available for any stock loan activities. I hereby expressly opt-out of any securities lending programs and instruct you to not loan out any of my shares.
Securities:[Number] shares of CYDY . (CYDY) and any CytoDyn shares subsequently acquired.
Please confirm receipt and compliance with this request.
Feed me shorts. I am hungry and cannot wait for Thanksgiving. Thanks again, $2024$ $CYDY$ Let's hear from Dr. Jay???
I didnt realize fda has approved our test
the reality is, my posts aren't going to change anything - and i'm tired of being negative here, as it doesn't really help anyone (including me). at the end of the day, it's just money, and i do think there is some chance one of the company's efforts yields some fruit at some point. part of my frustration is wanting a recovery in value in the near term - but it's just not realistic as even Jay has said we're in a re-boot phase.
i'm going to reduce or maybe totally retire from the whole chat board thing and remove the ticker from my phone and computer - it's just a healthier approach i think. and if something happens, it'll be a happy surprise. good luck to you and all longs.
People still pump this crap? After the bull run to end all bull runs in the market this past year?
The colorectal cancer trial will start enrolling in January, unless the FDA finds a way to screw it up. Dr. Lalezari has been undoing the damage, done by the previous management, and has made great strides in the last 11 months. He took over with the company near death. All of the investors would love for him to snap his fingers and fix everything overnight. Realistically, he has taken steps to salvage the clinical information, that was trashed by Amarex, and put that information to work in a fashion that will attract partners for MASH, HIV, and possibly other indications. He plans to set Leronlimab on course to become a cancer treatment for multiple types of cancers. Plus there is a possibility of a buyout. However, he has to build value back into the product, and company, before that can happen. Dr. Max Lataillade is very well connected, and may very well be in to work on getting long lasting Leronlimab into a position for a partner to take over HIV possibilities. Perhaps Dr. Lalezari is more concerned with getting this product, and company positioned for real value, so that the share price is no longer controlled by market makers, hedge funds and naysayers. If you are, in fact, still an investor, you should be excited about events lining up. Yet, I see you repeatedly calling for the progress to stop, then, restart with new management to try and get you your 50 cents.
I do agree that we need to get Tanya out. She served a purpose, but that purpose is no longer needed.
trust me - if i thought they were close, i wouldn't be negative. That's the whole point. I don't get how supposed longs are not more frustrated and pushing for change - after a 10 year cumulative return of -82%. No that's not a typo.
I follow the news and listen to the calls - and i have no clue the timing of catalysts that could change that. sure, the MASH results were good, but not statistically significantly better than the current SOC (Madrigal) - so zero chance we break into the market that way - i mean, why change current SOC if it's not that clear your drug is better. and in terms of other trials, we're nowhere close to even starting with humans - and human trials take years to enroll, get results, etc.
but maybe i should look on the bright side - we're only down 80% over 10 years, currently near all time lows, with no human trials on the horizon, and not a ton of money. Wait, is that the bright side?
message deleted, I am selling every stock. there is no proof that CYDY has any value and no one wants to have any desire to participate for ten years ow how boring and disappointing. Time to sell.
They get their $5.95 no matter what. Beats me though where they pick these jokers up.
Imagine not giving credit where due. CYDY has taken the punches and keeps right on
improving step by step. Meanwhile, many shareholders are so looking forward to the
PR where trial has begun. A trial that is a result of the many trials previous and the scientific data
which compelled the FDA to greenlight the new beginning.
I believe I predicted by Halloween. With the FDA though, who
knows when. Fine with me, I know the leronlimab formula is going to be a big big drug one
day. Even granny said so. I think she had a fling with Erap when she was living in the Philippines.
$$CYDY$$ 2024 Keep it going Dr. Jay. Fine job thus far. Buying all dips worthy.
Scared of Cytodyn succeeding. The closer they get, the more negative you get.
Before you accuse someone of lying, get your eyes checked!! My cryptic info was taken from the company's website. Sheesh! I even included the link! Did you actually make any effort at all? And, clowny, I never claimed they cured Alzheimer's. You guys are in such a hurry to make false accusations and argue facts.
Scared? Scared of what? This investment is down 85% over the past 5 years - at this point if the remaining 15% goes to zero, so what?
It's too bad that we have shareholders like you, who are happy to lose money year after year - looking out to the rainbow that is just over the horizon. Get a clue - we're in the 1st inning of a 5 year track to see any results in human trials.
So yeah, i do want to see change - because we're lower now than we were before any of these "great developments". Add to that the poor communication and lack of clarity.
No company is claiming to cure Alzheimer's. But the FDA has cleared a number of new treatments recently:
Alzheimer's: Are newly approved drugs making a real-life difference?
After a lull of nearly 2 decades, the Food and Drug Administration (FDA) has approved some novel drugs for the treatment of Alzheimer’s disease since 2021. Most of these drugs are antibody therapies targeting toxic protein aggregates in the brain. Their approval has sparked enthusiasm and controversy in equal measure. The core question remains: Are these drugs making a real difference? In this Special Feature, we investigate.
https://www.medicalnewstoday.com/articles/alzheimers-are-newly-approved-drugs-making-a-real-life-difference
And then there's this:
Three promising drugs for treating Alzheimer's disease bring fresh hope
Of particular interest:
Semaglutide is a medication primarily known for its use in managing type 2 diabetes and, more recently, aiding in weight loss. It's sold as a pill and marketed under the brand names Ozempic and Wegovy. Research into people taking drugs like semaglutide for diabetes showed that they had a reduced risk of developing dementia. This led to clinical trials to test the potential role of semaglutide in helping to treat Alzheimer's disease.
Semaglutide works by mimicking a natural hormone in the body that stimulates insulin production and reduces blood sugar levels. Scientists believe that this mechanism might also be beneficial for the brain. By improving insulin sensitivity and potentially interacting with receptors involved in learning and brain cell protection, semaglutide could potentially slow the progression of Alzheimer's disease.
https://www.alzheimers.org.uk/blog/three-promising-drugs-for-treating-alzheimers-disease-bring-fresh-hope
Please, share your link where you found that the company claimed to cure Alzheimer's Disease. You guys live to lie, don't you?
Pretty typical of a penny stock pharma to keep changing "its product" to whatever is the hot topic of the moment. Didn't this company go from "curing Covid" to well I'll let them tell you...
Here is a comparison between NASA and SpaceX. Which one gets more bang for the buck? https://www.inverse.com/innovation/sls-vs-starship
Which makes one wonder if the FDA was a joint private enterprise... how much would the taxpayer be saved and how much sooner would drugs get approved or dissapproved?
It's a good thing we don't rely totally on the government or we would already be wiped out long ago.
So looking forward to the FDA getting off high center. $CYDY$ 2024
been reading a lot of posts and company news. Boredom is what I see. all these years of promises and next year will be better , made me decide, that February 2024 will be the deadline for me o get rid of this loosing stock.
Enogph is enouph . February 3024 will be the deadline to get rid of this losing stock.
You cant make money with no trials. Why hasnt trial started. The drug may be great, but if you cant prove it,your stock is 14c
Well, I certainly drew out all the non-believers. That was a good bait tactic.
Seriously though, the creation of Leronlimab was not made in a carpenter's shop. If one were to tabulate the costs of Pro 141, the early and recent trials,
it would be an astounding number. Oh, and the manpower, maybe not close to government numbers (landing on the moon) because it is a private enterprise, astounding in itself, nonetheless a gargantuan effort to bring a Mab to success. Now, the trick is to show its efficacy with the few $ it has left to attract a
partner with $.
What is interesting about you 4 here and others on this board since 2016 is the degree that you twist the blade to make sure that life is of no
importance. Think about that. Leronlimab is the complete and utter opposite because it saves lives from experiencing unimaginable death.
Nader Poorhussain (CEO) and Scott Kelly (Chairman of the Board) certainly were a 2 man wrecking crew to CYDY shareholder equity!
Actually - it took 400,000 people to get those 2 people to the moon. A monumental effort by any measurement.
https://www.floridatoday.com/story/tech/science/space/2019/07/14/moon-landing-made-possible-400-000-workers/1559511001/
And the amount of money it took by today's money is astounding:
https://www.planetary.org/space-policy/cost-of-apollo
Please,are you kidding all of us.
This is the dumbest post I've seen on here by a long shot.
"a skeleton crew with limited money. That's spot on."
Wasn't it a crew of 2 that landed on the moon?
Fear makes people negative. You must be scared. Maybe you should sell and move on. Just because you have no idea what this management team's got going, for possible partnership(s), you feel the need to post negatively about them not following your plan. In less than a year, they have set goals and have delivered on them in order. They have made great strides in restoring credibility to the company reputation and data. The funding, for the upcoming clinical for colorectal cancer, is taken care of, per Dr Lalezari. The mouse studies are helping to clarify some of the previous abnormalities, brought about by Amarex's poor work, and to reinforce the multiplatform capabilities of Leronlimab. This is very necessary to chose the right path forward and to be able to negotiate with prospective partners. This management team is focused and is delivering. You're just upset because they're not doing things your way. Leave! Take your whiney butt somewhere else. Or, have patience, and you will be rewarded for staying strong. Pick what you want to do.
And here I was giving credit to a new hire and you didn't appreciate it? The guy has made it very clear that what I've said for years is true. You buy a penny stock to hold for weeks, not years.....if at all.
You should really try learning from a successful investor.
Amazing all the work done by our skeleton crew just since March of this year when Dr. Jay and FDA ended the hold. I suggest anyone interested in knowing more about leronlimab to go to the web site www.cytodyn.com and as always a good place to begin doing real due diligence. Upon such basic research it should be evident that the company is going to attract many collaborators in the upcoming 2025.
Our CRO, "Syneos Health has helped to develop or commercialize 92% of novel new drugs approved by the FDA in the last five years (2019-2023) and 91% of products granted marketing authorization by the European Medicines Agency." Now that is impressive and they are working to increase that with leronlimab.
Shouldn't be too much longer for this to begin: https://www.cancernetwork.com/view/fda-holds-meeting-for-leronlimab-rationale-dosing-in-ccr5-mss-mcrc
Lots of room for improvements and lots of room for leronlimab. "At present, only approximately 30% of cancer patients who receive pembrolizumab or nivolumab treatment for solid tumors will have lasting clinical responses to these agents. Extracellular vesicles (EVs) produced by tumors have been implicated in resistance to anti-PD-1 therapies as well as the spread of cancers."
As well, wondering how Dr. Sacha's presentation in Peru earlier this month was received. Nice to get out of the USA for some less biased real opinions based on science and not trash talk by competing pharmaceutical interests. India might be a great other place to start some trials. I expect something of this nature once a trial begins in USA. It will open many doors. The greatest investigators are those with independent analytical methods that look under every rock and search out compelling arguments of all kinds both pro and con. On this I predict from all I have read that leronlimab will one day reign supreme in this upcoming era of A.I..
$$CYDY$$ 2024 Excellent administration Dr. Jay.
You are right. Why are ww hiring hiv guys now. Our total focus should be cancer. We need trials of our drug by itself or in combo with other drugs. Has the fda given us go ahead on new trial?
someone wrote this is a skeleton crew with limited money. That's spot on. the money that we received from Amarex, and the $ from the Paulson warrant offering $ will last at most another 9-12 months i would assume. and those infusions were truly the last ditch efforts. there will be no appetite for another raise, unless it's at 5 cents. And i wouldn't participate in a 5 cent offering at this point.
my point is that the current mouse trial model isn't going to work - this company won't survive long enough. figure out a way to monetize, and at least return some cash to investors - i've said 50 cents for a sale - even that is likely a stretch. but otherwise, this company will die on the vine, and the drug gets picked up in bankruptcy. good deal for the bankruptcy buyer, but a zero for current equity holders.
this is why the market value of the company is lower now than it was before the hold was lifted, and before the $ was received. it's because the current plan isn't working - and even having more time and some more money won't fix that.
Your exactly right. Again,we should have our sole goal on dping cancer trials. If we do this we have a chance. If we keep waisting time on hiv ,we will never move forward
Ha ha. Or is it yada yada yada?
Either way. I hope (not) one of these days, certainly by 2032 you will do some Cydy homework.
Don't kid yourself. This is a skeleton crew trying to stay afloat Yea they've had some wins the last year but they need money and people to get these trials rolling They would be wise to focus on one indication and not go chasing rainbows like the last regime. They should do 1 trial to try and attract a partner. They don't have the horsepower or money to go it alone. Just my opinion. Good luck to you
Congrats! In his own words, you only have years to wait to see if you have a product. Come back in 2032, may be a great buy
https://www.facebook.com/ViiVHealthcare/videos/clinical-development-at-viiv-healthcare-max-lataillade/1627777744011871/
Of course, other companies are years ahead of you.....not to mention the companies Max left years ago
See everyone, this is called Homework!
I love this company since the turn around especially. Dr. Jay keeps hammering away bringing us step by step advancements. Dr. Lataillade, "he most recently served as Vice President, Head of Early Development and Global Research Strategy at ViiV Healthcare, where he oversaw its novel HIV oral and long-acting pipeline. Prior to that, he was Vice President and Head of Global Development for HIV at Bristol-Myers Squibb, having joined the global clinical research group in 2007 as an infectious disease and HIV specialist. Dr. Lataillade is also currently an assistant clinical professor and teaching attending at the Yale University School of Medicine.
Contacts at the FDA while at Bristol Meyers Squibb and ViiV Healthcare will surely be put to good use. Look for these networking skills to show up again here in CytoDyn.... tik tok.
$$$CYDY$$$ Leronlimab, the fuss continues with companies having good volume and remarkable products so bring it on short stumpers. I'm hongreeee.
Ok what has she done. Stock collapsed under her. Gave warrants so paulson could cash in. Tell me about the great job she has done. No science experience ,and she is leading board. You must be on board. This stock has floundered under her leadership. Seems strange she was lead counsel for paulson,and she is allowed to make warrant decisions that hugely benefit them.
Haha, how bout you eat it fool, I’m not dumping anything, you are wrong again
Tanya is not the CEO. She is the Chairman Of The Board.
Fellow longs ,we have to get tanya out. She is holding us up. How can we have a ceo with no science backround running a science company? How can we have her telling jay and others what to do . She is former consul for paulson. She made the warrants decision. It was paulson that greatly benefited. Until we get a sciece director,we will be stagnant.. What has she done to help us? Since her being ceo,the stock has sunk. I ask you fellow longs to rise up and remove her
Let’s talk about the fool. Anecdotally speaking: when Leronlimab has been injected into an infected HIV individual, they have beaten the disease. Published, verifiable data points to the efficacy of Leronlimab.
Here, you are doing your best to denigrate an HIV mab.
Obviously it’s your choice to reject a efficacious product, but who is really the fool?
Hahahaha eat it fool! Everyone dumping on your ass now! I love being right!!!!
You act like you know everything,but you never hafe facts. You only tellothers to look.
And, once again you make a false post. Guess again.
Aren't you worried you just gave me $5.95?
Followers
|
814
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
233700
|
Created
|
11/18/05
|
Type
|
Free
|
Moderators janice shell kgromax |
DISCLAIMER:
Securities and Exchange Commission and Department of Justice Investigations
The Company has received subpoenas from the United States Securities and Exchange Commission requesting documents and information concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19 and related communications with the FDA, investors, and others, and trading in the securities of CytoDyn. The SEC has informed the Company that this inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity or securities trading activity.
In addition, the Company and certain of its executives have received subpoenas in connection with an investigation being conducted by the United States Department of Justice. The subpoenas seek testimony and/or records concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19 and related communications with the FDA, investors, and others, and trading in the securities of CytoDyn.
Securities and Exchange Commission and Department of Justice Investigations
The Company has received subpoenas from the United States Securities and Exchange Commission (“SEC”) and the United States Department of Justice (“DOJ”) requesting documents and information concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19, HIV, and triple-negative breast cancer, related communications with the FDA, investors, and others, litigation involving former employees, the Company’s retention of investor relations consultants, and trading in the Company’s securities. Certain Company executives have received subpoenas concerning similar issues and may be interviewed by the DOJ or SEC in the future. The SEC informed the Company that its inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity or security.
The Company is cooperating fully with these non-public, fact-finding investigations, and as of the date of this filing, the Company is unable to predict the ultimate outcome and cannot reasonably estimate the potential possible loss or range of loss, if any.
VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its HIV program and a full clinical hold on its COVID-19 program in the United States. Further, the Company elected to pause its Brazil COVID-19 trials pending results from its previously scheduled data safety monitoring committee meeting and is in the process of reevaluating the timing of its HIV BLA resubmission.
The Company was not enrolling any new patients in the trials placed on hold in the United States. The partial clinical hold on the HIV program impacts patients currently enrolled in extension trials. These patients will be transitioned to other available therapeutics and no clinical studies can be initiated or resumed until the partial clinical hold is resolved. CytoDyn intends to work closely with the FDA to resolve the partial clinical hold as soon as possible. Under the full clinical hold on the COVID-19 program, no new clinical studies may be initiated until the clinical hold is resolved. The Company is not currently conducting any COVID-19 trials in the United States, as it is evaluating the most optimal programs on which to focus its resources and attention.
“CytoDyn is committed to FDA compliance,” said Scott A. Kelly, M.D., Chief Medical Officer of CytoDyn. “We are evaluating our clinical programs and are working to resolve the issues underlying the clinical holds as soon as possible in close communication with the FDA. We will provide an update when we have additional information.”
Up to 205,652,848 Shares of Common Stock
This prospectus supplement updates, amends and supplements the prospectus dated October 11, 2023, relating to our Registration Statement on Form S-1 (Registration No. 333-272815) (as supplemented or amended from time to time, the “Prospectus”). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.
This prospectus supplement is being filed to supplement the Prospectus with the following information:
The information in this prospectus supplement includes forward-looking statements relating to, among other things, future clinical trials and our business strategy. The reader is cautioned not to rely on these statements, which are based on our current expectations. Please see below for additional information about risks involving our securities.
This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference. The Prospectus, together with this prospectus supplement, relates to the resale of up to 74,903,789 shares of our common stock, par value $0.001 per share (the “common stock”), and 130,749,059 shares of our common stock underlying certain warrants (collectively, the “Shares”), by the selling stockholders identified in the Prospectus under “Selling Stockholders”.
Our common stock is quoted on the OTCQB of OTC Markets Group, Inc. under the symbol “CYDY.” On February 29, 2024 the closing price of our common stock was $0.2575 per share.
Investing in our securities involves risk. You should carefully consider the risks that we have described under the section captioned “Risk Factors” in the Prospectus on page 8 and in Part II, Item 1A of the 2024 Second Quarter 10-Q before buying our securities.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is March 1, 2024.
November 3, 2023
November 2023 Letter to Shareholders
Dear Shareholders,
We write to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), and to thank you for your continued support of the Company.
Throughout our history, CytoDyn has made great strides in developing leronlimab from a single indication molecule into a platform molecule with the potential for multiple therapeutic indications. Through CytoDyn’s investment in clinical trials, we have generated valuable data demonstrating how leronlimab might be used in HIV, oncology, metabolic dysfunction-associated steatohepatitis (“MASH” formerly “NASH”), and metabolic dysfunction-associated steatotic liver disease (“MASLD”). We have also successfully transferred our manufacturing technology allowing us to manufacture leronlimab at scale in preparation for clinical trials and potential FDA approval.
Fiscal year 2023 proved to be a very difficult year for CytoDyn. We had planned to be off clinical hold and back to conducting clinical trials by now. Unfortunately, to date, we have been delayed in our efforts to satisfy the FDA with our clinical hold submission(s). We have embarked on a more comprehensive effort to resolve the FDA’s lingering questions. These efforts include the Company’s hosting of a number of advisory board meetings with key opinion leaders (KOLs). Adding to our delay was the unanticipated medical leave taken by our then President, Dr. Arman creating additional delays in our subsequent resubmission.
However, these unforeseen circumstances provided the time needed to help us gain new insights and understanding of leronlimab in the current HIV treatment environment. Further, we were able to receive and incorporate the perspectives of some of the top HIV KOLs worldwide as to how they believe leronlimab can play a significant role in helping HIV patients, notwithstanding other therapeutic options currently available to patients. As part of this process, the Company engaged various new clinical, regulatory, and medical consultants and advisors with relevant experience and expertise that we believe will continue to benefit the Company for years to come.
The Company has taken necessary actions to position us for near-term and long-term success. During the last fiscal year, the Company implemented significant reductions to its workforce, cash burn rate, and operating expenses, in order to conserve our resources and devote them to critical corporate priorities. In addition to our work in HIV, we have worked with top experts to develop a MASH clinical trial protocol and identify potential MASH pre-clinical combination therapy trial concepts, which trials we believe could be attractive to a partner and position the Company for a greater chance of success within the MASH space. We also began development of a longer-acting therapeutic with a partner who has a very strong and reputable artificial intelligence (“AI”) platform, which we believe may provide significant increases in shareholder value in the years to come. We also believe that the Company is positioned for success in the Amarex litigation. We fully funded Sidley Austin LLP – the preeminent law firm representing the Company in this matter, filed a more-detailed statement of claim, and scheduled a final hearing date (August 12, 2024) in the arbitration.
We understand that CytoDyn’s recent challenges may have tested your confidence. We want to assure you that we remain dedicated to developing important therapeutics that can make a difference in
patients' lives, and at the same time provide value for our shareholders. Again, we are grateful for your ongoing support and trust.
We will continue our efforts to prioritize and execute on goals that will enhance value for all shareholders. Our efforts are focused on successfully completing the resolution of the FDA’s partial clinical hold – having recently made a submission that we hope will be successful – and strengthening our leadership team. Additionally, the Company will be evaluating the various potential indications for leronlimab to maximize the effective and efficient use of our resources. We have always believed leronlimab holds great promise, and we are determined to explore all avenues by which patients and medical practitioners can benefit from its use. We believe that with the improvements we have made and continue to pursue, our company is positioned for long-term success.
We deeply value your investment in CytoDyn and are committed to acting in your best interests. We look forward to continuing to communicate as additional developments occur. We realize the updates above may not answer all the questions you have. We therefore include a November 2023 “Frequently Asked Questions” supplement with this letter. This FAQ supplement is something we intend to update from time to time and it will be posted on the Company’s website in the near future.
Finally, in advance of our upcoming Annual Meeting on November 9, 2023, we want to remind you to submit your votes, if you have not already done so. If you were a shareholder as of September 11, 2023, you are considered a shareholder of record. Notably, the Company has asked for the shareholders’ approval to amend the Company’s Certificate of Incorporation to increase the total number of authorized shares of common stock. This increased share allowance is critical to the ongoing viability of the Company, and we therefore encourage everyone to vote if you have not already done so. If you have any questions or require any assistance in voting your shares, please call the Company’s proxy solicitor, Alliance Advisors LLC, at (833) 814-9456.
Sincerely,
Tanya Durkee Urbach
Board Chair
Note Regarding Forward-Looking Statements
This letter and the accompanying Frequently Asked Questions supplement contain forward-looking statements relating to, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and/or our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review the Annual Report on Form 10-K for the fiscal year ended May 31, 2023, including in the sections captioned “Forward Looking Statements” and “Item 1A. Risk Factors”, as later supplemented by our Form 10-Q for the quarter ended August 31, 2023, in the section captioned “Item 1A. Risk Factors”. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |